Company profile

Virogenics, Inc.

Privately held: no public share price (Commercial developer and INDUSTRY lead sponsor of the CMS121 Phase 1 (NCT05318040). The underlying composition patent is assigned to the Salk Institute; no public source documents a formal Salk-to-Virogenics licence, so Virogenics is recorded as developer rather than IP owner.) · USA

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
CMS121No recent activity
Phase 1
Undisclosed / early pipelineSmall molecule
Alzheimer's Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.